Akebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) CEO John P. Butler sold 144,250 shares of the company's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $2.10, for a total value of $302,925.00. Following the transaction, the chief executive officer now directly owns 2,604,330 shares in the company, valued at approximately $5,469,093. The trade was a 5.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Akebia Therapeutics Trading Down 0.9 %
AKBA stock traded down $0.02 during midday trading on Friday, reaching $2.14. 1,436,637 shares of the company's stock traded hands, compared to its average volume of 2,410,518. Akebia Therapeutics, Inc. has a 52-week low of $0.80 and a 52-week high of $2.48. The stock has a market cap of $466.91 million, a P/E ratio of -9.30 and a beta of 0.74. The stock's 50-day moving average is $2.01 and its 200 day moving average is $1.69.
Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.06). The company had revenue of $37.43 million during the quarter, compared to the consensus estimate of $45.66 million. During the same quarter in the prior year, the company posted ($0.08) earnings per share. As a group, research analysts expect that Akebia Therapeutics, Inc. will post -0.3 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $7.50 target price on shares of Akebia Therapeutics in a research report on Thursday, January 23rd. StockNews.com downgraded Akebia Therapeutics from a "hold" rating to a "sell" rating in a report on Wednesday, January 15th.
Read Our Latest Research Report on Akebia Therapeutics
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the stock. Wealth Effects LLC lifted its holdings in Akebia Therapeutics by 18.5% during the fourth quarter. Wealth Effects LLC now owns 32,000 shares of the biopharmaceutical company's stock valued at $61,000 after purchasing an additional 5,000 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Akebia Therapeutics by 10.9% during the third quarter. JPMorgan Chase & Co. now owns 98,546 shares of the biopharmaceutical company's stock valued at $130,000 after acquiring an additional 9,662 shares during the period. SRS Capital Advisors Inc. purchased a new position in shares of Akebia Therapeutics in the fourth quarter valued at about $26,000. MetLife Investment Management LLC boosted its stake in shares of Akebia Therapeutics by 25.7% in the third quarter. MetLife Investment Management LLC now owns 68,064 shares of the biopharmaceutical company's stock worth $90,000 after acquiring an additional 13,907 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Akebia Therapeutics by 3.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 586,710 shares of the biopharmaceutical company's stock worth $1,115,000 after purchasing an additional 18,043 shares in the last quarter. Institutional investors own 33.92% of the company's stock.
About Akebia Therapeutics
(
Get Free Report)
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.
Featured Stories

Before you consider Akebia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Akebia Therapeutics wasn't on the list.
While Akebia Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.